|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We studied global gene expression in three melanoma cell lines with the most common and potent V600E mutation in the B-RAF gene-four cell lines with a common Q61R mutation in the N-RAS gene and three cell lines with no mutations using human HG-U133A 2.0 micro-arrays with 22 277 transcripts.
|
15760917 |
2005 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Reciprocally, overexpression of C-MYC in normal melanocytes suppressed BRAF(V600E)-induced senescence more efficiently than NRAS(Q61R)-induced senescence, which agrees with the generally higher rates of activating mutations in BRAF than NRAS gene in human cutaneous me</span>lanomas.
|
18679422 |
2008 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions.
|
20149136 |
2010 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
|
20406486 |
2010 |
|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
|
21107323 |
2010 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
NRAS-mutant melanoma: response to chemotherapy.
|
21576590 |
2011 |